2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension : The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT
Copyright © 2019. Published by Elsevier Inc..
The European Pediatric Pulmonary Vascular Disease Network is a registered, non-profit organization that strives to define and develop effective, innovative diagnostic methods and treatment options in all forms of pediatric pulmonary hypertensive vascular disease, including pulmonary hypertension (PH) associated with bronchopulmonary dysplasia, PH associated with congenital heart disease (CHD), persistent PH of the newborn, and related cardiac dysfunction. The executive writing group members conducted searches of the PubMed/MEDLINE bibliographic database (1990-2018) and held face-to-face and web-based meetings. Ten section task forces voted on the updated recommendations, based on the 2016 executive summary. Clinical trials, meta-analyses, guidelines, and other articles that include pediatric data were searched using the term "pulmonary hypertension" and other keywords. Class of recommendation (COR) and level of evidence (LOE) were assigned based on European Society of Cardiology/American Heart Association definitions and on pediatric data only, or on adult studies that included >10% children or studies that enrolled adults with CHD. New definitions by the World Symposium on Pulmonary Hypertension 2018 were included. We generated 10 tables with graded recommendations (COR/LOE). The topics include diagnosis/monitoring, genetics/biomarkers, cardiac catheterization, echocardiography, cardiac magnetic resonance/chest computed tomography, associated forms of PH, intensive care unit/lung transplantation, and treatment of pediatric PH. For the first time, a set of specific recommendations on the management of PH in middle- and low-income regions was developed. Taken together, these executive, up-to-date guidelines provide a specific, comprehensive, detailed but practical framework for the optimal clinical care of children and young adults with PH.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
---|---|
Enthalten in: |
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation - 38(2019), 9 vom: 26. Sept., Seite 879-901 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hansmann, Georg [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 10.12.2020 Date Revised 10.03.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.healun.2019.06.022 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM301043302 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM301043302 | ||
003 | DE-627 | ||
005 | 20231225103818.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.healun.2019.06.022 |2 doi | |
028 | 5 | 2 | |a pubmed24n1003.xml |
035 | |a (DE-627)NLM301043302 | ||
035 | |a (NLM)31495407 | ||
035 | |a (PII)S1053-2498(19)31564-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hansmann, Georg |e verfasserin |4 aut | |
245 | 1 | 0 | |a 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension |b The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.12.2020 | ||
500 | |a Date Revised 10.03.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2019. Published by Elsevier Inc. | ||
520 | |a The European Pediatric Pulmonary Vascular Disease Network is a registered, non-profit organization that strives to define and develop effective, innovative diagnostic methods and treatment options in all forms of pediatric pulmonary hypertensive vascular disease, including pulmonary hypertension (PH) associated with bronchopulmonary dysplasia, PH associated with congenital heart disease (CHD), persistent PH of the newborn, and related cardiac dysfunction. The executive writing group members conducted searches of the PubMed/MEDLINE bibliographic database (1990-2018) and held face-to-face and web-based meetings. Ten section task forces voted on the updated recommendations, based on the 2016 executive summary. Clinical trials, meta-analyses, guidelines, and other articles that include pediatric data were searched using the term "pulmonary hypertension" and other keywords. Class of recommendation (COR) and level of evidence (LOE) were assigned based on European Society of Cardiology/American Heart Association definitions and on pediatric data only, or on adult studies that included >10% children or studies that enrolled adults with CHD. New definitions by the World Symposium on Pulmonary Hypertension 2018 were included. We generated 10 tables with graded recommendations (COR/LOE). The topics include diagnosis/monitoring, genetics/biomarkers, cardiac catheterization, echocardiography, cardiac magnetic resonance/chest computed tomography, associated forms of PH, intensive care unit/lung transplantation, and treatment of pediatric PH. For the first time, a set of specific recommendations on the management of PH in middle- and low-income regions was developed. Taken together, these executive, up-to-date guidelines provide a specific, comprehensive, detailed but practical framework for the optimal clinical care of children and young adults with PH | ||
650 | 4 | |a Consensus Development Conference | |
650 | 4 | |a Editorial | |
650 | 4 | |a Practice Guideline | |
650 | 4 | |a European Pediatric Pulmonary Vascular Disease Network | |
650 | 4 | |a children | |
650 | 4 | |a congenital heart disease | |
650 | 4 | |a guidelines | |
650 | 4 | |a pediatric | |
650 | 4 | |a pulmonary hypertension | |
650 | 4 | |a pulmonary vascular disease | |
650 | 4 | |a right heart failure | |
650 | 4 | |a right ventricle | |
700 | 1 | |a Koestenberger, Martin |e verfasserin |4 aut | |
700 | 1 | |a Alastalo, Tero-Pekka |e verfasserin |4 aut | |
700 | 1 | |a Apitz, Christian |e verfasserin |4 aut | |
700 | 1 | |a Austin, Eric D |e verfasserin |4 aut | |
700 | 1 | |a Bonnet, Damien |e verfasserin |4 aut | |
700 | 1 | |a Budts, Werner |e verfasserin |4 aut | |
700 | 1 | |a D'Alto, Michele |e verfasserin |4 aut | |
700 | 1 | |a Gatzoulis, Michael A |e verfasserin |4 aut | |
700 | 1 | |a Hasan, Babar S |e verfasserin |4 aut | |
700 | 1 | |a Kozlik-Feldmann, Rainer |e verfasserin |4 aut | |
700 | 1 | |a Kumar, R Krishna |e verfasserin |4 aut | |
700 | 1 | |a Lammers, Astrid E |e verfasserin |4 aut | |
700 | 1 | |a Latus, Heiner |e verfasserin |4 aut | |
700 | 1 | |a Michel-Behnke, Ina |e verfasserin |4 aut | |
700 | 1 | |a Miera, Oliver |e verfasserin |4 aut | |
700 | 1 | |a Morrell, Nicholas W |e verfasserin |4 aut | |
700 | 1 | |a Pieles, Guido |e verfasserin |4 aut | |
700 | 1 | |a Quandt, Daniel |e verfasserin |4 aut | |
700 | 1 | |a Sallmon, Hannes |e verfasserin |4 aut | |
700 | 1 | |a Schranz, Dietmar |e verfasserin |4 aut | |
700 | 1 | |a Tran-Lundmark, Karin |e verfasserin |4 aut | |
700 | 1 | |a Tulloh, Robert M R |e verfasserin |4 aut | |
700 | 1 | |a Warnecke, Gregor |e verfasserin |4 aut | |
700 | 1 | |a Wåhlander, Håkan |e verfasserin |4 aut | |
700 | 1 | |a Weber, Sven C |e verfasserin |4 aut | |
700 | 1 | |a Zartner, Peter |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation |d 1993 |g 38(2019), 9 vom: 26. Sept., Seite 879-901 |w (DE-627)NLM012612367 |x 1557-3117 |7 nnns |
773 | 1 | 8 | |g volume:38 |g year:2019 |g number:9 |g day:26 |g month:09 |g pages:879-901 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.healun.2019.06.022 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 38 |j 2019 |e 9 |b 26 |c 09 |h 879-901 |